Homology Medicines Statistics Share Statistics Homology Medicines has 3.23M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 3.23M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 2.04M Failed to Deliver (FTD) Shares 50 FTD / Avg. Volume 0.17%
Short Selling Information The latest short interest is 405.03K, so 0% of the outstanding
shares have been sold short.
Short Interest 405.03K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 2.56
Valuation Ratios The PE ratio is -0.18 and the forward
PE ratio is -0.99.
Homology Medicines's PEG ratio is
0.
PE Ratio -0.18 Forward PE -0.99 PS Ratio 0 Forward PS 1.5 PB Ratio 1.54 P/FCF Ratio -0.13 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Homology Medicines.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.97,
with a Debt / Equity ratio of 1.54.
Current Ratio 4.97 Quick Ratio 4.97 Debt / Equity 1.54 Debt / EBITDA -0.13 Debt / FCF -0.13 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-6.82M Employee Count 7 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -21K Effective Tax Rate 0.05%
Stock Price Statistics The stock price has increased by -0.5% in the
last 52 weeks. The beta is -0.11, so Homology Medicines's
price volatility has been lower than the market average.
Beta -0.11 52-Week Price Change -0.5% 50-Day Moving Average 0.78 200-Day Moving Average 0.91 Relative Strength Index (RSI) 65.97 Average Volume (20 Days) 29,535
Income Statement
Revenue n/a Gross Profit n/a Operating Income -66.1M Net Income -47.73M EBITDA -66.1M EBIT n/a Earnings Per Share (EPS) -5.12
Full Income Statement Balance Sheet The company has 77.97M in cash and 8.73M in
debt, giving a net cash position of 69.23M.
Cash & Cash Equivalents 77.97M Total Debt 8.73M Net Cash 69.23M Retained Earnings -234.81M Total Assets 79.07M Working Capital 54.05M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -67.72M
and capital expenditures -75K, giving a free cash flow of -67.79M.
Operating Cash Flow -67.72M Capital Expenditures -75K Free Cash Flow -67.79M FCF Per Share -7.27
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields FIXX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for FIXX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 25, 2024. It was a
backward
split with a ratio of 1:18.
Last Split Date Mar 25, 2024 Split Type backward Split Ratio 1:18
Scores Altman Z-Score -6.16 Piotroski F-Score 0
